Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Ohana Biosciences

Headquarters: Cambridge, MA, United States of America
Year Founded: 2016
Status: Archived

Historical deals and financings can be found by searching the organization's name in the BCIQ Deals and Financing Modules.

BioCentury | Sep 25, 2023
Management Tracks

Remy Sukhija leaving Madrigal as CCO

Plus: Editas hires Caren Deardorf as chief commercial and strategy officer, and updates from ProFound and hC
BioCentury | Jul 13, 2022
Emerging Company Profile

Epic Bio: Epigenome editing via compact components

Horizons Ventures leads $55M series A for start-up developing compact epigenome editors with all-in-one AAV delivery
BioCentury | Feb 11, 2022
Management Tracks

Silberstein joins GentiBio as CFO

Plus new CTO, CDO at Finch; and updates from Generation Bio, Atea and more
BioCentury | Jul 8, 2021
Management Tracks

Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more

Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
BioCentury | May 1, 2021
Regulation

April 30 Quick Takes: Bilenker has $212M to build newco Treeline’s toolbox; plus Farxiga, Opdivo, BioCryst, Leo, Hikma and more  

An SEC filing released Friday revealed that Josh Bilenker and Jeffrey Engelman have $212 million to begin building newly launched Treeline Biosciences Inc.’s toolbox for chasing validated but
BioCentury | Apr 2, 2020
Finance

Billion-dollar funds from Arch, Flagship show VCs are open for business

War chests show interest in biotech hasn’t waned amid pandemic
BioCentury | Jan 27, 2020
Emerging Company Profile

Ohana: Looking to the other half of reproductive biology

Ohana is applying single cell sequencing to the unexplored male half of reproductive biology
Items per page:
1 - 10 of 11